Halozyme Therapeutics, Inc. (HALO) Posts Narrower than Expected Q1 Loss
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $68.99 +0.64%
EPS Growth %: +17.5%
Financial Fact:
Total revenues: 31.85M
Today's EPS Names:
OCCI, MAYS, CRMT, More
EPS Growth %: +17.5%
Financial Fact:
Total revenues: 31.85M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Join SI Premium – FREE
Halozyme Therapeutics, Inc. (NASDAQ: HALO) reported Q1 loss of ($0.10), $0.03 better than the analyst estimate of ($0.13). Revenue for the quarter came in at $7.5 million versus the consensus estimate of $5.19 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ennis (EBF) Reports In-Line Q1 EPS
- Smith & Wesson Brands (SWBI) Tops Q4 EPS by 15c
- John Wiley & Sons, Inc. (WLYB) Tops Q4 EPS by 12c; Offers Outlook
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
